CAR vs IOVA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CAR and IOVA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CAR and IOVA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Avis Budget Group runs one of the three big global vehicle-rental platforms, operating the Avis, Budget, Budget Truck, Payless and Zipcar brands across airport, off-airport, urban and international markets. Revenue comes from renting a large owned-and-leased vehicle fleet, and the economics hinge on utilization, per-day pricing and the residual value of cars when they are sold out of the fleet. The company competes with privately held Enterprise Holdings, Hertz, Europe's Sixt, and peer-to-peer platforms like Turo and Getaround.

Full CAR guide

Iovance Biotherapeutics (Nasdaq: IOVA) develops tumor-infiltrating lymphocyte (TIL) cell therapies, individualized treatments made from a patient's own immune cells. Its lead product, Amtagvi (lifileucel), became the first FDA-approved one-time T-cell therapy for a solid tumor when it was cleared for advanced melanoma, and the company also sells Proleukin, an interleukin-2 product used alongside TIL treatment. Iovance manufactures Amtagvi in-house at its Iovance Cell Therapy Center and has treated more than 1,500 patients across commercial and clinical use, with regulatory approvals in the US, Canada and Australia and decisions in the UK, Switzerland and Europe still pending.

Full IOVA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CAR drivers: Fleet utilization and pricing recovery; Vehicle residual values and fleet mix.
• IOVA drivers: Amtagvi commercial ramp; In-house manufacturing and margin scale.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The equity is small relative to enormous fleet and corporate debt, so modest swings in used-car residual values, interest rates or demand can move the stock sharply, and the shares carry a beta well above the market. For IOVA, iovance remains unprofitable and has historically funded operations with stock sales, so ongoing dilution is a real risk to existing shareholders.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CAR if you believe its drivers more; IOVA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CAR and IOVA guides.

CAR. CAR still does not screen on a trailing price-to-earnings basis because trailing EPS is negative (about -$18), so investors lean on forward earnings (about 21x) and enterprise-value-to-EBITDA (about 21x on trailing EBITDA of roughly $1.54 billion, an EV dominated by fleet debt). At about 0.33x sales and with negative book equity, the stock behaves like a leveraged call on the rental cycle. Figures are approximate and drawn from the company's disclosures through the second quarter of 2026 and consensus estimates as of October 16, 2026.

IOVA. Iovance now trades at roughly 19 times trailing revenue, up from about five times in mid-2026, a multiple that reflects rapid growth expectations rather than current earnings, since the company is still posting net losses. Losses have been narrowing as Amtagvi revenue scales and margins improve, and analysts expect revenue near $413 million in 2026 and $594 million in 2027. The 10 analysts tracked have a mean target of about $14.40, close to the current price after the rally, so valuation hinges on whether the ramp keeps beating the raised guidance.

Headline figures (approximate, October 2026): CAR shows revenue (ttm) ~$11.7B, revenue (q2 2026) ~$3.0B, down ~1.3% YoY, q2 2026 eps (actual vs est.) $0.98 vs ~$1.85, net loss (ttm) ~$636M; IOVA shows revenue (ttm) ~$325M; Q2 2026 ~$99M, up ~66% year over year, fy2026 revenue guidance ~$410M to $420M (raised Sept 29 from $350M to $370M), gross margin (ttm) ~48%; operating margin ~-52%, net loss ~$290M TTM; Q2 2026 ~$47M (EPS -$0.11 vs -$0.13 est.).

CAR and IOVA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CAR and IOVA exposure against your real portfolio. It is not an investment adviser.